Oncothyreon Inc $2.89

down 0.00


24/4/2014 08:10 PM  |  NASDAQ : ONTY  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get ONTY Trend Analysis - it has underperformed the S&P 500 by 9%

Partner Headlines

  1. Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ...

    Benzinga
  2. Oncothyreon Says ONT-380 Showed Acceptable Safety Profile

    Benzinga
  3. Five Stocks Making Moves Under $10

    Benzinga
  4. Benzinga's Top Pre-Market Gainers

    Benzinga
  5. US Stock Futures Drop Ahead Of New Home Sales, Durable Goods Data

    Benzinga
  6. Oncothyreon Reports Merck Serono Decision to Continue Development of Tecemotide

    Benzinga
  7. UPDATE: Piper Jaffray Initiates Oncothyreon at Underweight on Pipeline ...

    Benzinga
  8. UPDATE: Wedbush Securities Downgrades Oncothyreon to Neutral, Lowers PT

    Benzinga
  9. Stocks Hitting 52-Week Lows

    Benzinga
  10. Morning Market Losers

    Benzinga
  11. A Peek Into The Market Before The Trading Starts

    Benzinga
  12. Oncothyreon's L-BLP25 Did Not Meet Primary Endpoint in Lung Cancer Trial

    Benzinga
  13. Benzinga's Top Pre-Market Gainers

    Benzinga
  14. UPDATE: Stifel Nicolaus Initiates Oncothyreon at Buy with $10 PT on Stimuvax ...

    Benzinga
  15. Oncothyreon Announces Presentation of PX-866 Clinical Data at American ...

    Benzinga
  16. Stocks Plummet on Global Growth Worries

    MarketIntelligenceCenter
  17. Stocks Slide as Greece Deadline Approaches

    MarketIntelligenceCenter
  18. Oncothyreon Inc. (ONTY) Loses 37% On Wider-Than-Expected Loss

    MarketIntelligenceCenter
  19. Oncothyreon Plunges 40% on Earnings, Date of Final Stimuvax Results

    Benzinga
  20. Cantor Fitzgerald Maintains Buy on Oncothyreon; Phase III Start Trial Continues ...

    Benzinga
  21. Benzinga's Top Pre-Market Losers

    Benzinga
  22. UPDATE: JMP Securities Raises Price Target on Oncothyreon to $14

    Benzinga
  23. HF Manager Shkreli: Betting His Career that Oncothyreon's Stimuvax Drug ...

    Benzinga
  24. Oncothyreon Breeches HOD, Ready to Break Higher

    Benzinga
Trading Center